Table 4.
Hazard ratios for the combined occurrence of all‐cause death, heart failure event, and surrogate markers for end‐stage heart failure
| Variable | Univariate HR (95% CI) | P‐value |
|---|---|---|
| Tobacco use | 4.61 (1.30–16.39) | 0.02 |
| Baseline LVEF (5% increment) | 0.58 (0.39–0.87) | <0.01 |
| Severe mitral regurgitation | 4.58 (1.39–15.08) | 0.01 |
| Severe tricuspid regurgitation | 4.96 (1.02–24.03) | 0.047 |
| ACE‐inhibitor or angiotensin II receptor blocker | 0.23 (0.06–0.90) | 0.03 |
| Digitalis | 5.21 (1.52–17.86) | <0.01 |
| Oral anticoagulant | 4.37 (1.27–14.93) | 0.02 |
| Bromocriptine | 1.18 (0.15–9.31) | 0.88 |
ACE, angiotensin‐converting enzyme; CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction.
All variables significant at the 0.05 alpha level are presented. Bromocriptine is also presented as it was the main exposition variable.
The variable history of myocarditis was associated with an HR (95% CI) of 33.33 (3.06–333.33) based on a single patient and was therefore not included in the table.